Simvastatin
- Generic Name
- Simvastatin
- Brand Names
- Cholib, FloLipid, Simcor, Vytorin, Zocor
- Drug Type
- Small Molecule
- Chemical Formula
- C25H38O5
- CAS Number
- 79902-63-9
- Unique Ingredient Identifier
- AGG2FN16EV
- Background
Simvastatin, also known as the brand name product Zocor, is a lipid-lowering drug derived synthetically from a fermentation product of Aspergillus terreus. It belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liv...
- Indication
Simvastatin is indicated for the treatment of hyperlipidemia to reduce elevated total cholesterol (total-C), low-density lipoprotein cholesterol (LDL‑C), apolipoprotein B (Apo B), and triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C).
...
- Associated Conditions
- Cardiovascular Events, Diabetes Mellitus, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Mixed Hyperlipidemia, History of coronary heart disease cardiovascular event, History of stroke or other cerebrovascular disease cardiovascular event
- Associated Therapies
- -
Statin Therapy Vs. Therapeutic Lifestyle Changes and Supplements
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2006-08-17
- Lead Sponsor
- Chestnut Hill Health System
- Target Recruit Count
- 80
- Registration Number
- NCT00365742
Simvastatin Therapy in Women With Polycystic Ovary Syndrome.
- Conditions
- First Posted Date
- 2006-08-17
- Last Posted Date
- 2006-08-17
- Lead Sponsor
- Poznan University of Medical Sciences
- Registration Number
- NCT00365638
- Locations
- 🇵🇱
Division of Infertility and Reproductive Endocrinology, Department of Gynecology and Obsterics, Poznan, Poland
A Drug Interaction Study Between Tocilizumab, Methotrexate and Simvastatin on Patients With Rheumatoid Arthritis.
- Conditions
- Interventions
- First Posted Date
- 2006-08-16
- Last Posted Date
- 2010-06-11
- Lead Sponsor
- Hoffmann-La Roche
- Target Recruit Count
- 23
- Registration Number
- NCT00365001
Pharmacokinetic Drug Interactions of AEGR-733 on Lipid-lowering Agents
- Conditions
- First Posted Date
- 2006-08-02
- Last Posted Date
- 2018-02-23
- Lead Sponsor
- Aegerion Pharmaceuticals, Inc.
- Target Recruit Count
- 125
- Registration Number
- NCT00359281
- Locations
- 🇺🇸
University of Pennsylvania, Philadelphia, Pennsylvania, United States
Simvastatin and Anastrozole in Treating Postmenopausal Women With Ductal Carcinoma In Situ or Invasive Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2006-07-20
- Last Posted Date
- 2013-06-24
- Target Recruit Count
- 11
- Registration Number
- NCT00354640
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
Comparison of the Combination of Fenofibrate and 40 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
- Conditions
- Interventions
- First Posted Date
- 2006-07-14
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 450
- Registration Number
- NCT00352183
- Locations
- 🇱🇹
Site 508, Palanga, Lithuania
🇱🇹Site 506, Kaunas, Lithuania
🇦🇺Site 204, Adelaide, Australia
Comparison of the Combination of Fenofibrate and 20 mg Simvastatin Versus 40 mg Simvastatin Monotherapy
- First Posted Date
- 2006-07-07
- Last Posted Date
- 2009-07-08
- Lead Sponsor
- Solvay Pharmaceuticals
- Target Recruit Count
- 1040
- Registration Number
- NCT00349375
- Locations
- 🇨🇿
Site 013, Olomouc, Czech Republic
🇨🇿Site 001, Prague, Czech Republic
🇨🇿Site 017, Pribram, Czech Republic
Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors
- Conditions
- Interventions
- First Posted Date
- 2006-06-26
- Last Posted Date
- 2010-02-02
- Lead Sponsor
- Kowa Research Europe
- Target Recruit Count
- 178
- Registration Number
- NCT00344175
- Locations
- 🇸🇪
Huslakaren i Sandviken, Sandviken, Sweden
🇸🇪Hjarthuset AB, Varberg, Sweden
🇳🇱Kamerlingh Onnesstraat 16-18, Nijmegen, Netherlands
Simvastatin in Preventing a New Breast Cancer in Women at High Risk for a New Breast Cancer
- First Posted Date
- 2006-06-08
- Last Posted Date
- 2019-04-03
- Target Recruit Count
- 50
- Registration Number
- NCT00334542
- Locations
- 🇺🇸
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, Maryland, United States
🇺🇸Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Boston, Massachusetts, United States
Paroxysmal Atrial Fibrillation: Role of Inflammation, Oxidative Stress Injury and Effect of Statins
- First Posted Date
- 2006-05-04
- Last Posted Date
- 2015-01-01
- Lead Sponsor
- University of Calgary
- Target Recruit Count
- 40
- Registration Number
- NCT00321802
- Locations
- 🇨🇦
University of Calgary, Foothills Hospital, Calgary, Alberta, Canada
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.